Adicet Bio is a biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell therapies for cancer
Adicet Bio has raised $80.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
Adicet Bio's investors include OrbiMed, Regeneron, Pontifax, Novartis Venture Fund, KB Investment.
Adicet Bio is headquartered in Redwood City, United States.
Adicet Bio is a biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell therapies for cancer
Adicet Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Adicet Bio — Funding & Investors." VCBacked, October 7, 2025, https://www.vcbacked.co/company/adicet-bio. Accessed September 29, 2026.
VCBacked. (2025). Adicet Bio — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/adicet-bio
{{cite web |title=Adicet Bio — Funding & Investors |url=https://www.vcbacked.co/company/adicet-bio |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated